Stephen Sabba Sells Shares of Ligand Pharmaceuticals
Stephen Sabba sold 2,145 shares of Ligand Pharmaceuticals on June 16, 2026.
Key Points
- Stephen Sabba sold 2,145 shares of Ligand Pharmaceuticals on June 16, 2026, with no planned transaction code.
- Ligand Pharmaceuticals trades on NasdaqGM under LGND, with a market cap of $5.27 billion and a P/E ratio of 34.31.
- Institutional investors like BlackRock and Vanguard have made recent changes to their Ligand holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, Stephen Sabba sold 2,145 shares of Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). The transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Ligand Pharmaceuticals Incorporated
Stephen Sabba executed a sale of 2,145 shares at an unspecified price on June 16, 2026. This sale was not made under a Rule 10b5-1 plan. Earlier, on the same day, he had acquired the same number of shares at $66.13 each. Another insider, Jason Haas, sold 6,461 shares on June 12, 2026, at an average price of $255.58, following a purchase of 4,000 shares at $51.56.
Other Institutional Activity in Ligand Pharmaceuticals
BlackRock, Inc. increased its holdings by 21,692 shares, reaching a total of 2,961,923 shares valued at approximately $591.35 million. Vanguard Portfolio Management LLC took a new position with 1,100,267 shares worth about $219.67 million. Janus Henderson Group PLC added 14,491 shares, bringing its total to 1,009,891 shares valued at $201.62 million. Invesco Ltd. significantly boosted its stake by 307,140 shares, ending with 823,604 shares valued at $164.43 million.
Ligand Pharmaceuticals Incorporated Stock Down 3.4%
Shares of Ligand Pharmaceuticals are trading near $264.41. The company has a market cap of $5.27 billion with a P/E ratio of 34.31 and a forward P/E of 23.25. The stock's beta is 1.039, indicating moderate volatility. Over the past year, the stock has ranged from a low of $110.00 to a high of $267.27. Its 50-day moving average is $229.40, and its 200-day moving average is $200.85. The company maintains a robust current ratio of 21.28 and a quick ratio of 20.81, with a debt-to-equity ratio of 45.32.
Recent Earnings
Ligand Pharmaceuticals reported revenue of $274.48 million, showing a growth of 14.1%. The net margin stands at 55.95%, with a return on equity of 17.13%. Earnings per share were $7.67. The next earnings report is expected on August 6, 2026.
Analysts Set New Price Targets
On May 8, 2026, RBC Capital maintained its "buy" rating on Ligand Pharmaceuticals with a price target of $262.00. Earlier, on April 30, 2026, HC Wainwright & Co. also maintained a "buy" rating with a target of $289.00. Citigroup has consistently maintained a "buy" rating, setting a target of $282.00 on April 15, 2026. The consensus among analysts suggests a mean price target of $277.60, with 10 analysts currently offering opinions.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company based in Jupiter, Florida. It develops and licenses various biopharmaceutical assets worldwide. The company offers treatments for infectious diseases, multiple myeloma, osteoporosis, and more. Led by CEO Todd C. Davis, Ph.D., Ligand employs 47 people and operates within the healthcare sector, focusing on biotechnology.
Bottom Line
Stephen Sabba's recent sale of Ligand Pharmaceuticals shares is part of regular insider activity. Investors often watch insider transactions to gauge market sentiment. Ligand's stock remains well-regarded, with steady institutional interest and positive analyst ratings. Remember, insider trades are backward-looking and may not reflect current positions.
Get Ligand Pharmaceuticals Incorporated alerts
New 13F filings, insider trades, and analyst moves on $LGND, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.